Pediatric and Young Adult Cancer Incidence in the United States During the COVID‐19 Pandemic
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von David A Siegel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Neoplasms, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Background
Cancer incidence decreased during the COVID‐19 pandemic; this study describes cancer incidence changes for children, adolescents, and young adults during this period. We used US Cancer Statistics (USCS) to describe potential impacts of the pandemic on cancer incidence for persons 0–39 years.
Methods
We used data from USCS, covering 98% of the US population, to evaluate cancer case counts, incidence rates, and monthly counts; incidence rate ratios were calculated comparing year 2019 (baseline) to 2020 and 2021. We calculated trends using joinpoint regression for the period 2003–2021.
Results
Comparing 2019 with 2020, cancer incidence decreased 5% (95% confidence interval [CI], 3%–7%) for ages 0–19 years and 7% (95% CI, 6%–8%) for ages 20–39. For ages 0–19, decreases were seen for thyroid cancer, melanoma, and nonmalignant central nervous system (CNS) neoplasms. For ages 20–39, decreases were seen for leukemias, lymphomas, CNS neoplasms, sarcomas, melanoma, and some carcinoma types. Decreases in 2020 were least pronounced for the distant stage at diagnosis. For ages 0–39, new diagnoses were lowest during March or April 2020 but returned to prepandemic levels during the second half of 2020. Decreases in 2021 were consistent with previously decreasing trends for many cancer types.
Conclusions
Cancer rate decreases were largest for young adults (vs. children) and were significant for some cancer types. These findings might help assess the impacts of the COVID‐19 pandemic, inform investigations into potential causes of these decreases, and guide responses to future public health crises.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Division of Epidemiology/Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
- Baylor College of Medicine, Houston, Texas, USA.
- Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
ORCID-Profile: David A Siegel, Christine M Kava, Logan G Spector, Philip J Lupo, Eric B Durbin, Eric Tai, S Jane Henley
Förderung
- Intramural CDC HHS
Zitieren
APA
Siegel, D. A., Kava, C. M., Spector, L. G., Lupo, P. J., Durbin, E. B., Tai, E., & Henley, S. J. (2025). Pediatric and Young Adult Cancer Incidence in the United States During the COVID‐19 Pandemic. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31976
Vancouver
Siegel DA, Kava CM, Spector LG, Lupo PJ, Durbin EB, Tai E, et al. Pediatric and Young Adult Cancer Incidence in the United States During the COVID‐19 Pandemic. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31976
BibTeX
@article{Siegel2025,
author = {Siegel, David A and Kava, Christine M and Spector, Logan G and Lupo, Philip J and Durbin, Eric B and Tai, Eric and Henley, S Jane},
title = {Pediatric and Young Adult Cancer Incidence in the United States During the COVID‐19 Pandemic},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31976}
}
EUVIMED